Symbravo Tablet
NDC Package 81968-020-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Symbravo (meloxicam, rizatriptan) tablets is sYMBRAVO is indicated for the acute treatment of migraine with or without aura in adults.Limitations of UseSYMBRAVO should only be used where a clear diagnosis of migraine has been established. This formulation utilizes a tablet delivery system. Marketed by Axsome Therapeutics, Inc., this product is identified by NDC 81968-020 and is authorized under FDA application NDA215431.

Identification & Billing

NDC Package Code
81968-020-03
Package Description
1 BOTTLE in 1 CARTON / 3 TABLET in 1 BOTTLE
Product Code
81968-020
11-Digit Billing Format
81968002003
RxNorm Crosswalk
  • RxCUI: 2711789 - meloxicam 20 MG / rizatriptan 10 MG Oral Tablet
  • RxCUI: 2711789 - meloxicam 20 MG / rizatriptan 10 MG (as rizatriptan benzoate 14.5 MG) Oral Tablet
  • RxCUI: 2711795 - SYMBRAVO 20 MG / 10 MG Oral Tablet
  • RxCUI: 2711795 - meloxicam 20 MG / rizatriptan 10 MG Oral Tablet [Symbravo]
  • RxCUI: 2711795 - Symbravo (meloxicam 20 MG / rizatriptan 10 MG) Oral Tablet

Clinical Specifications

Proprietary Name
Symbravo
Non-Proprietary Name
Meloxicam, Rizatriptan
Substance Name
Meloxicam; Rizatriptan Benzoate
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
SYMBRAVO is indicated for the acute treatment of migraine with or without aura in adults.Limitations of UseSYMBRAVO should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with SYMBRAVO, the diagnosis of migraine should be reconsidered before SYMBRAVO is administered to treat any subsequent attacks.SYMBRAVO is not indicated for the preventive treatment of migraine attacks.SYMBRAVO is not indicated for the treatment of cluster headache.

Regulatory & Marketing

Labeler Name
Axsome Therapeutics, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA215431
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-19-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (81968-020). Click a package code to view its specific billing and regulatory data.

81968-020-02
1 BOTTLE in 1 CARTON / 2 TABLET in 1 BOTTLE
81968-020-09
9 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 81968-020-03 identifies a specific commercial package of 1 bottle in 1 carton / 3 tablet in 1 bottle of Symbravo, a human prescription drug labeled by Axsome Therapeutics, Inc.. This tablet is formulated for oral use and contains meloxicam; rizatriptan benzoate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Axsome Therapeutics, Inc. on May 19, 2025. The current certification is valid through December 31, 2026.

How is this Axsome Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 81968002003. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
81968-020-03
11-Digit CMS (5-4-2)
81968-0020-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.